Cite
A Multicenter Cohort Study of Dose-Dense Temozolomide (21 of 28 Days) for the Treatment of Recurrent Anaplastic Astrocytoma or Oligoastrocytoma.
MLA
Neyns, Bart, et al. “A Multicenter Cohort Study of Dose-Dense Temozolomide (21 of 28 Days) for the Treatment of Recurrent Anaplastic Astrocytoma or Oligoastrocytoma.” Cancer Investigation, vol. 26, no. 3, May 2008, pp. 269–77. EBSCOhost, https://doi.org/10.1080/07357900701708393.
APA
Neyns, B., Chaskis, C., Joosens, E., Menten, J., D’Hondt, L., Branle, F., Sadones, J., & Michotte, A. (2008). A Multicenter Cohort Study of Dose-Dense Temozolomide (21 of 28 Days) for the Treatment of Recurrent Anaplastic Astrocytoma or Oligoastrocytoma. Cancer Investigation, 26(3), 269–277. https://doi.org/10.1080/07357900701708393
Chicago
Neyns, Bart, Cristo Chaskis, Eric Joosens, Johan Menten, Lionel D’Hondt, Fabrice Branle, Jan Sadones, and Alex Michotte. 2008. “A Multicenter Cohort Study of Dose-Dense Temozolomide (21 of 28 Days) for the Treatment of Recurrent Anaplastic Astrocytoma or Oligoastrocytoma.” Cancer Investigation 26 (3): 269–77. doi:10.1080/07357900701708393.